According to a market research report from Meticulous Research, the infection control market is expected to grow at a compound annual growth rate (CAGR) of 13.3% to reach $58.2 billion by 2027.
Infection control is an essential measure across the health care industry to avoid infectious diseases. Factors such as the rising incidences of hospital-acquired infections, growing number of surgical procedures, increasing incidence of chronic diseases associated with the geriatric population and the growing medical device reprocessing industry are significantly impacting the growth of this market.
Infectious diseases are caused by pathogenic microorganisms, such as bacteria, viruses, parasites or fungi. These diseases can spread, directly or indirectly, either from one person to another, from infected or non-sterilized surgical or medical devices used to treat a person, or from being in the infected environment of any health care facility. Thus, to prevent and reduce the occurrence rate of infectious diseases, health care facilities adopt infection control methods and programs to improve the quality of care and provide a safe environment to the patients and other personnel working in the same facilities.
In recent years, it was observed that the rate of HAIs is on a continuous rise and includes common infections, such as bloodstream infections (BSIs), pneumonia, urinary tract infections (UTIs) and surgical site infections (SSIs). These infections can threaten a patient’s health and life and prolong hospital stays, thereby creating an additional economic burden. These infections contribute to about 10% of the total reported infections in developed and developing countries.
According to ECD Systems LLC data, the five most common types of HAIs, include surgical site infections (SSI), ventilator-associated pneumonia (VAP), central-line associated bloodstream infections (CABI), clostridium difficile infections (CDI) and catheter-associated urinary tract infections (CAUTI), cost around $ 9.8 billion annually in the U.S., with SSIs contributing the largest share of 33.7% ($3.3 billion). The high cost of SSIs is mainly because of prolonged hospitalization of patients and associated diagnostic tests and treatment. This leads to an increase in additional cost burden, and hence to reduce this burden, it is necessary to control infections that occur during surgical procedures. This is expected to drive the market for SSI control products in the coming years.
COVID-19 has had an impact on the infection control market.
With the severe outbreak of COVID-19, there is an unprecedented global demand for advanced health care facilities, services and infrastructure to treat the infected. Infection control products, such as personal protective equipment, has seen an unprecedented increase in demand from most countries worldwide to handle a surge of COVID-19 patients. Health care workers rely on personal protective equipment to protect themselves and their patients from being infected and infecting others. Due to growing cases of COVID-19, the available face masks and gowns capacity is insufficient, and the global health care industry is experiencing a shortfall. The WHO estimates that 89 million medical masks will be required every month. To meet that demand, a 40% increase in manufacturing is expected. The WHO also estimates that frontline workers would need approximately 7-10% of the world’s supply of surgical masks, and possibly more. For examination gloves, that figure goes up to 76 million, while international demand for goggles stands at 1.6 million per month.
From a demand perspective, nearly 70-80% of hospitals struggle with a shortage of ventilators, masks, other personal protective equipment, hospital beds, and other supplies. With disturbed supply chains and production capacity shortages, manufacturers of hospital beds and supplies cannot meet the demand. As a result, various countries with high infection rates face huge shortfalls for infection control products. The majorly impacted countries are present in the developed region, and thus to address this situation, government agencies in every country are focusing on alternative ways to increase the production capacity.
The infection control market study by Meticulous Research also evaluates industry competitors and analyzes the market at regional and country levels.
Geographically, North America is estimated to dominate the global infection control market in 2020, followed by Europe and Asia-Pacific. This growth in North America can be attributed to the increasing hospital and outpatient visits, rising number of surgical procedures, growing number of HAIs, increasing health care expenditure, growing pharma and biotech industry, increasing aging population with chronic diseases, and government initiatives to reduce HAIs and implement effective infection control practices.
However, Asia-Pacific is expected to grow at the fastest CAGR during the forecast period. The factors driving the growth of the APAC market include the economic growth of many countries, growing government focus on the health care sector, rising prevalence of infectious diseases, including COVID-19 and government initiatives for boosting infection control procedures.